Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.
Fiche publication
Date publication
avril 2024
Journal
JAMA network open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GALLAND Loïck
Tous les auteurs :
Frenel JS, Zeghondy J, Guérin-Charbonnel C, Mailliez A, Volant E, Poumeaud F, Patsouris A, Arnedos M, Bailleux C, Cabal J, Galland L, de Nonneville A, Guiu S, Dalenc F, Pistilli B, Bachelot T, Pierga JY, Le Du F, Bocquet F, Larrouquere L, Loirat D
Lien Pubmed
Résumé
Little is known regarding the outcomes associated with tucatinib combined with trastuzumab and capecitabine (TTC) after trastuzumab-deruxtecan exposure among patients with ERBB2 (previously HER2)-positive metastatic breast cancer (MBC).
Mots clés
Humans, Middle Aged, Female, Breast Neoplasms, drug therapy, Capecitabine, therapeutic use, Cohort Studies, Prospective Studies, Trastuzumab, therapeutic use, Brain Neoplasms, Disease Progression, Receptor, ErbB-2, Oxazoles, Pyridines, Quinazolines
Référence
JAMA Netw Open. 2024 04 1;7(4):e244435